| Factors |
Category |
p53 expression |
Pvalue |
| |
|
Negative (n=166) |
1+ (n=62) |
Overexpression (n=35) |
|
| Age (years) |
Mean±SD
(range) |
58.5±14.0
(25~87) |
54.4 ± 13.1 (26~81) |
58.3±12.8
(32~84) |
0.135 |
| Nuclear grade |
1,2 |
157 |
58 |
21 |
|
| |
3 |
4 |
2 |
13 (38%) |
<0.0001 |
| ER |
- |
11 |
5 |
21 (60%) |
|
| |
+ |
155 |
57 |
14 |
<0.0001 |
| PgR |
- |
19 |
10 |
26 (74%) |
|
| |
+ |
147 |
52 |
9 |
<0.0001 |
| HER2 |
- |
149 |
49 |
13 |
|
| |
+ |
16 |
12 |
22 (63%) |
<0.0001 |
| Ki-67 |
- |
141 |
44 |
8 |
|
| |
+ |
25 |
18 |
24 (69%) |
<0.0001 |
| Surgery |
Bp |
90 |
42 |
26 (74%) |
|
| |
Bt |
74 |
19 |
9 (26%) |
0.219 |
| Adjuvant therapy |
None |
113 |
41 |
26 (74%) |
|
| Chemotherapy |
0 |
1 |
5 |
|
| |
Endocrine therapy |
49 |
19 |
4 |
|
| |
Chemo-endocrine therapy |
3 |
0 |
0 |
|
| Subtype |
Luminal A-like |
125 |
38 |
4 (11%) |
|
| Luminal B-like |
18 |
10 |
6(17%) |
|
| HER2 |
3 |
3 |
18 (51%) |
|
| Luminal/HER2 |
13 |
9 |
4 (11%) |
|
| Triple Negative |
7 |
2 |
3 (9%) |
|
|
